Short Courses*
SUNDAY, APRIL 30
MORNING 10:00 am - 1:00 pm
SC1: Preclinical and Clinical Immunogenicity Bioanalysis: ADCs, Multi-Domain Biotherapeutics and New Modalities - View Detailed Agenda
Darshana Jani, M.S., Senior Manager, Pfizer, Inc.
Priya Sriraman, Ph.D., Principal Investigator, Biotherapeutics Development, Celgene Corp
Seema Kumar, Ph.D., Associate Director, EMD Serono
Corinna Krinos Fiorotti, Ph.D., Business Development Manager, Bioagilytix
SC2: Translational Considerations for Development of Monoclonal Antibodies Part I: Focus on Early Discovery - View Detailed Agenda
Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals
Enrique Escandon Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories
Vaishnavi Ganti, Ph.D., Associate Principal Scientist, Biologics Discovery-DMPK, Merck Research Laboratories
Veronica Juan, Ph.D., Principal Scientist, Protein Sciences, Merck Research Labs
Scott L. Klakamp, Ph.D., Principal, SKD Consulting LLC
Mohammad Tabrizi, Ph.D., Director Biologics Discovery, Merck Research Laboratories
SC3: Genomics in the Service of Cancer Immunotherapy - View Detailed Agenda
Zoltan Szallasi, Ph.D., M.D., Senior Research Scientist, Informatics Program; Assistant Professor, Pediatrics, Children’s Hospital Boston and Harvard Medical School
SC4: The Multi-Attribute Method (MAM) for Improving Product and Process Development - View Detailed Agenda
Richard Rogers, Ph.D., Scientist 4, Just Biotherapeutics
SC6: In silico Protein Docking - View Detailed Agenda
Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intexon Corp.
AFTERNOON 2:00 - 5:00 pm
SC7: Translational Considerations for Development of Monoclonal Antibodies Part II: Focus on Nonclinical Development to the Clinic - View Detailed Agenda
Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals
Enrique Escandon Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories
Vaishnavi Ganti, Ph.D., Associate Principal Scientist, Biologics Discovery-DMPK, Merck Research Laboratories
Veronica Juan, Ph.D., Principal Scientist, Protein Sciences, Merck Research Labs
Scott L. Klakamp, Ph.D., Principal, SKD Consulting LLC
Mohammad Tabrizi, Ph.D., Director Biologics Discovery, Merck Research Laboratories
SC8: In silico Immunogenicity Predictions – A Hands-On Workshop - View Detailed Agenda
Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intrexon Corp.
Paolo Marcatili, Ph.D., Asst. Professor, Bio and Health Informatics Department, Technical University of Denmark
SC9: Target Selection for Biologics - View Detailed Agenda
William R. Strohl, Ph.D., President, BiStro Biotech Consulting, LLC
SC11: Adoptive Therapy with CAR T Cells - View Detailed Agenda
Prasad S. Adusumilli, M.D., F.A.C.S., Associate Attending and Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center
Carl J DeSelm, M.D., Ph.D., Researcher, Immunotherapy, Memorial Sloan Kettering Cancer Center
Matthew J. Frigault, M.D., Clinical Fellow in Medicine, Dana-Farber Cancer Institute
Eric L. Smith, M.D., Ph.D., Assistant Attending, Myeloma Service; Director of Clinical Translation, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center
TUESDAY, MAY 2
DINNER 6:00 - 8:30 pm
SC12: Study Design and Statistical Data Analysis of Flow Cytometry Assays - View Detailed Agenda
Shuguang Huang, Ph.D., CSO, Stat4ward LLC
SC13: Phenotypic Screening Applications and Technologies - View Detailed Agenda
Steven Rust, Ph.D., Senior Manager, R&D, MedImmune
SC14: Overcoming the Challenges of Immunogenicity Assays, Risk Assessment and Regulatory Requirements - View Detailed Agenda
Jim McNally, Ph.D., Associate Director and Immunogenicity Expert, Global Early Development - Quantitative Pharmacology & Drug Disposition, EMD Serono
Bonnie Rup, Ph.D., Independent Consultant
DINNER 6:00 - 9:00 pm
SC17: Transient Protein Production in Mammalian Cells - View Detailed Agenda
Richard Altman, MS, Scientist, Protein Technologies, Amgen
Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.
Panelist: Barry A. Morse, Ph.D., Principal Research Scientist, Biologics Research, Janssen Research and Development
THURSDAY, MAY 4
DINNER 5:45 - 8:15 pm
SC15: Critical Considerations for the Design and Development of Antibody-Drug Conjugates - View Detailed Agenda
Isabel Figueroa, Ph.D., Scientist, PTPK, Genentech, Inc.
Shawn Owen, Ph.D., Assistant Professor, Pharmaceutics and Pharmaceutical Chemistry; and Adjunct Professor, Internal Medicine, University of Utah
SC16: New USP Initiatives for Characterization and Release of Biologics - View Detailed Agenda
Maura C. Kibbey, Ph.D., Director Science & Standards, Global Biologics, US Pharmacopeia
Steven L. Walfish, Ph.D., Principal Science & Standards Liaison, US Pharmacopeia
SC18: Clinical Prospects of Cancer Immunotherapy - View Detailed Agenda
Gaurav Goel, M.D., Assistant Professor, Division of Medical Oncology, Medicine, University of Kentucky Markey Cancer Center
SC19: Strategic Bioassay Design and Analysis - View Detailed Agenda
Liming Shi, MS, MA, Senior Group Leader, Bioassay Development, Hospira, a Pfizer Company
*Separate Registration Required